Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 1:44 |
Clinical Application of DCISionRT |
| 4:40 |
Clinical Evidence |
Julie Margenthaler, MD, FACS
Breast Surgeon, Siteman Cancer Center, Washington University School of Medicine St Louis, Missouri
| 10:30 |
Patient Discussion and Clinical Application |
| 13:43 |
100 Patient Analysis |
| 20:40 |
Case Studies |
Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 23:31 |
DCIS Biosignature Score and Residual Risk Subtype |
Panel Discussion with the Speakers: Multidisciplinary Perspectives – Q/A Discussion
| 33:32 |
Treatment Recommendations for Residual Risk Type |
| 39:08 |
Treatment with Endocrine Therapy for patients under 50 years old with a low-risk vs elevated score |
| 50:54 |
Additional Ongoing Research – Troy Bremer, PhD |
| 51:48 |
Final Thoughts – Julie Margenthaler, MD, FACS and Chirag Shah, MD |
Closing Remarks
| 53:13 |
Closing Remarks from Troy Bremer, PhD |
